FGFR
Catalog No. | Inhibitor Name | FGFR | FGFR1 | FGFR2 | FGFR3 | FGFR4 | Other |
---|---|---|---|---|---|---|---|
A10080 | Ponatinib | **** | Abl,PDGFRα,VEGFR2 | ||||
A11159 | BGJ398 | **** | **** | **** | ** | VEGFR2,Lyn,Kit | |
A10137 | Nintedanib | ** | ** | ** | * | VEGFR3,VEGFR2,LCK | |
A10703 | PD173074 | ** | VEGFR2,c-Src | ||||
A11411 | Dovitinib | *** | *** | FLT3,c-Kit,VEGFR3/FLT4 | |||
A11075 | AZD4547 | **** | **** | **** | * | KDR,IGFR | |
A10715 | Danusertib | ** | Aurora A,Abl,TrkA | ||||
A10953 | Orantinib | * | PDGFRβ,Flk1 | ||||
A10254 | Brivanib | * | VEGFR2,Flk1,VEGFR1 | ||||
A10198 | Dovitinib Dilactic Acid | *** | *** | FLT3,c-Kit,VEGFR3/FLT4 | |||
A11753 | MK-2461 | ** | ** | ** | |||
A10162 | Brivanib Alaninate | * | VEGFR2,Flk1,VEGFR1 | ||||
A13211 | SSR128129E | * | VEGFR2,PDGFRβ | ||||
A11558 | SU5402 | ** | |||||
A15534 | BLU9931 | * | * | * | **** | ||
A12357 | FIIN-2 | **** | *** | ** | ** | FLT3,c-Kit,VEGFR3/FLT4 | |
A14415 | CH5183284 | *** | *** | *** | * | VEGFR2 | |
A11244 | LY2874455 | **** | **** | *** | *** | ||
A15957 | Erdafitinib | ||||||
A10508 | KW-2449 | ** | FLT3, Bcr-Abl, Aurora A, PDGFRβ, IGF-1R, EGFR | ||||
A10699 | Pazopanib HCl | * | VEGFR1, VEGFR2, VEGFR3, PDGFR, c-Kit, c-Fms | ||||
A11518 | Pazopanib | * | VEGFR1, VEGFR2, VEGFR3, PDGFR, c-Kit, c-Fms | ||||
A13111 | R 1530 | * | Chk2, KDR, FGFR, Aurora A, Cdk2, VEGFR-2, PDGFRβ | ||||
A15073 | E-3810 | *** | ** | VEGFR1, VEGFR2, VEGFR3 | |||
A15848 | FIIN-3 | *** | ** | ** | ** | ||
A15957 | Alofanib (RPT835) |
Notes:
1.Hover mouse over " " to view the IC50 value.(A few compounds have proven potency but without published IC50 data.)
2.For more details about the compound, click on the product name of your interest.
3.The higher the number of " " is, the more potent the inhibitor or activator is.
4."" refers to compounds which do inhibitory effects on the related isoform, but without specific value.
-
Debio-1347 (CH5183284)
Catalog No. A14415 FGFR1/2/3 抑制剂Debio-1347 (CH5183284)是成纤维细胞生长因子受体亚型1(FGFR-1),2(FGFR-2)和3(FGFR-3)的生物利用抑制剂,具有潜在的抗肿瘤活性。 了解更多 -
NVP-BGJ398 phosphate
Catalog No. A15194 FGFR 抑制剂NVP-BGJ398 phosphate是一种新型的选择性泛特异性FGFR抑制剂,对FGFR1,FGFR2和FGFR3的IC50分别为0.9、1.4和1 nM。与FGFR4和VEGFR2相比,对FGFR具有40倍以上的选择性,并且对Abl,Fyn,Kit,Lck,Lyn和Yes的活性很小。 了解更多 -
FIIN-2
Catalog No. A12357 -
Alofanib (RPT835)
Catalog No. A15946 -
Erdafitinib (JNJ-42756493)
Catalog No. A15957 FGFR 抑制剂Erdafitinib (JNJ-42756493)是一种有效且选择性的口服生物利用型泛成纤维细胞生长因子受体(FGFR)抑制剂,具有潜在的抗肿瘤活性。 了解更多 -
H3B-6527
Catalog No. A16252 -
Derazantinib (ARQ-087)
Catalog No. A16825 FGFR 抑制剂Derazantinib (ARQ-087)是成纤维细胞生长因子受体(FGFR)的口服生物利用抑制剂,对于FGFR2的IC50值为1.8 nM,对于FGFR1和3的IC50值为4.5 nM,对FGFR4的效力较低(IC50 = 34 nM)。它还抑制RET,DDR2,PDGFRβ,VEGFR和KIT。 了解更多 -
Rogaratinib
Catalog No. A16963 -
FGFR1/DDR2 inhibitor 1
Catalog No. A18716 FGFR1/DDR2 inhibitorFGFR1/DDR2 inhibitor 1 is an inhibitor of fibroblast growth factor receptor 1 (FGFR1) and discoindin domain receptor 2 (DDR2), with IC50 values of 31.1 nM, 108.4 nM and 3.2 nM for FGFR1, KG-1, and DDR2, respectively. 了解更多 -
Roblitinib
Catalog No. A19431 FGFR4 inhibitorRoblitinib (FGF-401; Compound Example 83) is a highly selective and potent FGFR4 inhibitor with an IC50 of 1.9 nM. Roblitinib has antitumor activity. 了解更多 -
Dovitinib lactate
Catalog No. A21851 FGFR3 inhibitorDovitinib(CHIR-258; TKI258) lactate is a potent inhibitor of fibroblast growth factor receptor 3 (FGFR3) with an IC50 of 5 nM. 了解更多 -
LY 2874455
Catalog No. A11244 -
Dovitinib Dilactic acid (TKI258 Dilactic acid)
Catalog No. A10198 RTK 抑制剂Dovitinib是一种小分子多靶点酪氨酸激酶抑制剂,可抑制通过ZNF198-FGFR1或BCR-FGFR1转化为IL3独立性的Ba / F3细胞,IC50值分别为150 nM和90 nM。 了解更多 -
Brivanib alaninate (BMS-582664)
Catalog No. A10162 -
Dovitinib (TKI-258)
Catalog No. A11411 RTK 抑制剂Dovitinib是一种小分子多靶点酪氨酸激酶抑制剂,可抑制通过ZNF198-FGFR1或BCR-FGFR1转化为IL3独立性的Ba / F3细胞,IC50值分别为150 nM和90 nM。 了解更多 -
AP24534 (Ponatinib)
Catalog No. A10080 BCR-ABL 抑制剂AP24534 (Ponatinib)是有效的多激酶和pan-BCR-ABL抑制剂。 了解更多 -
Danusertib (PHA-739358)
Catalog No. A10715 Aurora 抑制剂Danusertib (PHA-739358)是Aurora A/B/C的Aurora激酶抑制剂,在无细胞分析中的IC50为13 nM/79nM/61 nM,对Abl,TrkA,c-RET和FGFR1以及更低的浓度具有中等效力 对Lck,VEGFR2/3,c-Kit,CDK2等有效。 了解更多 -
Bibf1120 (Nintedanib)
Catalog No. A10137 VEGFR 抑制剂Bibf1120 (Nintedanib)是一种新型的三联血管激酶抑制剂,可同时抑制三种生长因子受体:VEGFR,PDGF和FGFR。 了解更多 -
TSU-68 (Orantinib, SU6668)
Catalog No. A10953 PDFGRβ 抑制剂TSU-68 (Orantinib,SU6668)在无细胞试验中具有8 nM的Ki对PDGFR自磷酸化的最大效力,但也强烈抑制Flk-1和FGFR1反磷酸化,对IGF-1R,Met,Src, Lck,Zap70,Abl和CDK2; 不抑制EGFR。 了解更多 -
Brivanib (BMS-540215)
Catalog No. A10254 VEGFR-2 抑制剂Brivanib (BMS-540215)是一种VEGFR-2抑制剂,IC50为25 nM,Ki为26 nM。 了解更多 -
Nintedanib esylate
Catalog No. A16197 RTK 抑制剂Nintedanib esylate是多种受体酪氨酸激酶(RTK)和非受体酪氨酸激酶(nRTK)的有效抑制剂。 了解更多 -
BGJ398 (NVP-BGJ398)
Catalog No. A11159 FGFR 抑制剂BGJ398 (NVP-BGJ398)是一种有效的选择性抑制剂,具有成纤维细胞生长因子受体(FGFR)酪氨酸激酶1、2、3和4的潜在抗血管生成和抗肿瘤活性(对于FGFR1,FGFR2,FGFR3,IC50值为0.9、1.4、1.0和60 nM, 和FGFR4)。 了解更多 -
Pazopanib HCl (GW786034)
Catalog No. A10699 VEGFR/PDGFR/FGFR 抑制剂Pazopanib HCl (GW786034)是VEGFR-1,VEGFR-2,VEGFR-3,PDGFR-a/β和c-kit的有效且选择性的多靶点酪氨酸激酶抑制剂,可阻止肿瘤生长并抑制血管生成。 了解更多 -
FIIN-3
Catalog No. A15848 -
Pazopanib (GW-786034)
Catalog No. A11518 VEGFR 抑制剂Pazopanib (GW-786034)是VEGFR-1,VEGFR-2,VEGFR-3,PDGFR-a/β和c-kit的有效且选择性的多靶点酪氨酸激酶抑制剂,可阻止肿瘤生长并抑制血管生成。 了解更多